Jacobo E. Mintzer, MD, is the Executive Director of Clinical Research and the Alzheimer’s Disease Research Center, at the Roper St. Francis Clinical Biotechnology Research Institute in Charleston, SC. He is also a professor in the department of Health Studies at the Medical University of South Carolina (MUSC) and a staff physician at the Ralph H. Johnson VA Medical Center. At MUSC, he developed the Geriatric Psychiatry and Alzheimer’s research program in 1991, which includes inpatient, outpatient, and consultation services as well as a fellowship program. Dr. Jacobo Mintzer has been involved in clinical research on Alzheimer’s disease for the last 20 years.
Dr. Mintzer is a distinguished fellow with the American Psychiatric Association. Dr. Mintzer is former treasurer and board member for the American Association for Geriatric Psychiatry (AAGP). He is former member of the American Psychiatric Association (APA) Council on Aging and Co-Chair of the Scientific Committee for the 2003 meeting of the International Psychogeriatric Association (IPA). Additionally, he is the former Chair of the APA Committee on Ethnic Minority Elderly Committee. Dr. Mintzer’s clinical interests are concentrated on geriatric psychiatry and medicine, Alzheimer’s disease and psychopharmacology of Alzheimer’s disease, behavioral management of agitated demented patients, memory disorders, and mental health in the elderly as a function of ethnicity.
Dr. Mintzer earned his medical degree at the University in Buenos Aires, Argentina. He completed an internship and a five-year residency at the Hadassah-Hebrew University School of Medicine in Jerusalem, Israel, and a fellowship in geriatric psychiatry at the University of California in Los Angeles. Dr Mintzer is fluent in five languages.
Industry Expertise (7)
Areas of Expertise (4)
Buenos Aires University: M.D., Psychiatry 1978
- American Psychiatric Association (APA)
- International Psychogeriatric Association (IPA)
- APA Committee on Ethnic Minority Elderly
- Clinical Center and Special Projects Review Committee (CCSP)
Media Appearances (5)
The musical mind: trailblazing brain images of local cellist’s performance
The Post and Courier online
Jacobo Mintzer, executive director of the Clinical Biotechnology Research Institute at Roper St. Francis and an Alzheimer’s Disease expert, had attended a spring solo recital by Norbert Lewandowski, principal cellist in the Charleston Symphony Orchestra.
The recital included contemporary works that relied on sampling and digitally rendered audio. Lewandowski had recorded himself playing various parts, as required by the musical score, then performed live in conjunction with the recorded lines.
Mintzer was mesmerized by the music and impressed with the cellist’s power of concentration and emotional investment. “He was not reading the notes,” Mintzer recalled. “Most of the time, he would play with his eyes closed, and that was kind of curious to me.”...
Angel Partners leader plans exit
The Post and Courier online
Marshall’s experience with entrepreneurs will be an asset in her new role, said Dr. Jacobo Mintzer, director of Roper’s biotechnology institute.
“Her expertise will be extremely valuable as we grow our innovation center” and seek to create “a hub for biotechnology innovation,” he said...
Jews Express Solidarity In Wake Of Charleston Church Shooting
The Jewish Week online
Describing the greater Charleston community as “historic, resilient, and strong,” the congregation’s president, Jacobo Mintzer, said that “Synagogue Emanu-El joins in the mourning and commits to promote and share strongly and unconditionally in the healing process.”
“Today, we are all members of the Emanuel AME Church of Charleston,” he wrote...
Jacobo Mintzer and the plight of Jewish Argentines
The Post and Courier online
In 1991, Jacobo Mintzer, a psychiatrist who specializes in Alzheimer’s disease, arrived in Charleston with his wife, Olga Brawman Mintzer, a researcher of anxiety disorders. He had pursued a circuitous medical career that led him from his native Argentina, which he left in 1979, to Israel and then the U.S...
New Roper research institute helps lure Israeli biotech firm
Charleston City Paper online
Roper's Clinical Biotechnology Research Institute (CBRI), established in March 2013, takes up part of the fifth floor of Pettit Tower on the hospital's downtown campus. According to Dr. Jacobo Mintzer, executive director of CBRI, the institute connects patient care with clinical research. This means that patients in the Roper healthcare system can seek out cutting-edge treatments, and companies and doctors with new ideas can test them out at Roper.
"The only condition we request from the company is that they will have a promising approach and that they will agree to establish their headquarters in Charleston," Mintzer says...
Featured Articles (5)
OBJECTIVE: To evaluate the efficacy and safety of memantine in patients with mild to moderate Alzheimer's disease (AD) receiving cholinesterase inhibitor (ChEI) treatment. Methods: Participants (N= 433) with probable AD, Mini-Mental State Exam (MMSE) scores between 10-22 (inclusive), and concurrent stable use of ChEIs (donepezil, rivastigmine, galantamine) were randomized to placebo or memantine (20 mg once daily) for 24 weeks...
BACKGROUND: Mild cognitive impairment (MCI) represents a transitional state between the cognitive changes of normal aging and very early dementia and is becoming increasingly recognized as a risk factor for Alzheimer disease (AD). The Memory Impairment Study ...
Dementia with Lewy bodies (DLB) is the second commonest cause of neurodegenerative dementia in older people. It is part of the range of clinical presentations that share a neuritic pathology based on abnormal aggregation of the synaptic protein α-synuclein. DLB has ...
OBJECTIVE: The authors examined the effect of the acetylcholinesterase inhibitor donepezil on magnetic resonance markers of neurodegeneration in Alzheimer's disease.
METHOD: In this randomized, double-blind, placebo-controlled pilot study, 67 patients with mild to ...
BACKGROUND: We report the findings from the first large, double-blind, placebo-controlled study conducted to evaluate the efficacy and safety of risperidone in the treatment of psychotic and behavioral symptoms in institutionalized elderly patients with dementia. ...